WEI-LI SHAO

President @OmadaHealth

[WEI-LI SHAO @weilishao]

5/5: The next challenge is making sure it’s the right person, on the right med, at the right time. It’s important to implement wraparound care that treats obesity as part of an integrated cardiometabolic strategy, protects muscle and function, and supports long-term use where appropriate. Biology meeting behavior is where durability will get decided.

[WEI-LI SHAO @weilishao]

1/5 GLP-1s are not “weight-loss drugs” anymore. They are cardiometabolic drugs, and in this case even MSK drugs, that also lower weight. Retatrutide’s new Phase 3 data just made that very hard to ignore.

[WEI-LI SHAO @weilishao]

4/5: That should change how we talk about GLP-1 spend. This is no longer a “nice-to-have” weight benefit off in the corner of the pharmacy budget.

[WEI-LI SHAO @weilishao]

The obesity drug race isn’t about “who hits 30% weight loss” anymore.

With these next‑gen agents, the financial risk climbs with the efficacy: early stops, complications, and churn all show up in the benefits budget.

The real question for employers and plans: not “Which drug?” but “Which care model keeps people on therapy appropriately, protects function, and keeps total cost of care stable?”

Great reporting by @TreedinDC at @axios on where this market is headed.

https://t.co/kRkfvOxiKH

[WEI-LI SHAO @weilishao]

There’s no such thing as a silver bullet without tarnish. GLP-1s are an incredible innovation benefiting millions. But they’ve got their ups and downs. With the right support, the downsides can be largely mitigated.

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

While many benefits of #obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with #GLP-1 receptor agonist-based therapies https://t.co/IFPyEU8bKn
#weightloss

[WEI-LI SHAO @weilishao]

@WSJ GLP-1s are powerful. But it lends to a fixation on biology alone.

The real goal isn’t just pounds lost. It’s durable health: muscle preservation, better nutrition, more movement, and sustained behavior change.

Medication can drive weight loss. Care makes it last.

[WEI-LI SHAO @weilishao]

14 day response is profound.

[WEI-LI SHAO @weilishao]

Incredibly promising. Single dose with 18 month durability.

VERVE‑102 resulted in dose-dependent mean reductions in PCSK9 ranging from 51% to 88%, at the lowest 0.3 mg/kg dose to the highest 1.0 mg/kg dose, respectively.

https://t.co/pbgxMyu5Nq

[WEI-LI SHAO @weilishao]

Gaming changing LDL-C reductions. Could change the entire game for cardiovascular disease.

[WEI-LI SHAO @weilishao]

These reductions were sustained over time, with durability observed for up to 18 months following treatment.

[WEI-LI SHAO @weilishao]

Retatrutide could bend the obesity curve in ways we haven't imagined.

But the gap between trial results and real-world outcomes is exactly where the last generation of GLP-1s got lost. The data doesn't translate on its own.

The drug is ready. The system around it still has to catch up

[WEI-LI SHAO @weilishao]

Retatrutide's Phase 3 data is extraordinary. But the question I keep coming back to: will the infrastructure exist to deliver these results in the real world?

The best-selling drug of all time won't be won by efficacy alone. It'll be won by whoever builds the support system that makes 28% weight loss reproducible outside a clinical trial.

[WEI-LI SHAO @weilishao]

@ezraklein 3/3 The sweet spot is the convergence of GLP-1s with lifestyle programs backed up by evidence + the daily work between visits. 🎙️ https://t.co/CMWm4p41R5

[WEI-LI SHAO @weilishao]

1/3 @EzraKlein last week: GLP-1s might be "the biggest pharmaceutical story since antidepressants." 1 in 8 American adults is on one. The market is "the Wild West of wellness."

[WEI-LI SHAO @weilishao]

@ezraklein 2/3 18 years inside pharma: the drugs are a breakthrough. The system around them is unreliable. Compounding shortcuts, prescriber-light telehealth, no lifestyle scaffolding, no guardrails for who comes off and how.

[WEI-LI SHAO @weilishao]

Employers want to cover GLP-1s, but the path forward is opaque. They’re juggling how to implement coverage while making it financially sustainable - for them and their employees.

To meet this need, we announced @OmadaHealth will participate in @LillyPad’s Employer Connect program—adding another way to pair GLP‑1 access with our GLP-1 Care Track for coordinated, virtual lifestyle support before, during, and after medication.

Between PBM solutions, Lilly’s Employer Connect, and Omada’s GLP‑1 Flex Care, employers now have a fuller menu.

Our latest survey of 3,000+ GLP‑1 patients underscores why this matters: access alone isn’t enough.

Learn more in the press release: https://t.co/2Mmf4R2G6f

[WEI-LI SHAO @weilishao]

@OmadaHealth's Q1 2026 was a milestone quarter — 1M+ Total Members (+51% YoY), revenue +42% YoY to $78M, narrowed GAAP net loss, and positive Adjusted EBITDA (non-GAAP) in our highest-cost quarter.

Beyond the numbers, our growth levers showed up clearly this quarter:

🔁 Reach: broadened relationships with PBMs, health plans, and employers
📣 Enrollment: passed 1M Total Members with growth across our full cardiometabolic suite
💡 Engagement: Continued advancements in OmadaSpark and Meal Map.
🔼 Raised full-year guidance for revenue and AEBITDA

Omada is becoming the connective tissue between how employers buy, how members engage, and how outcomes are delivered across the cardiometabolic landscape.

Learn more about our Q1 results, including a reconciliation of GAAP to non-GAAP measures: https://t.co/GxchZgmNUF

$OMDA